leucovorin calcium / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 424 Diseases   809 Trials   809 Trials   14393 News 


«12...111112113114115116117118119120121...235236»
  • ||||||||||  Imfinzi (durvalumab) / AstraZeneca
    Durvalumab (MEDI 4736) with extended neoadjuvant regimens in rectal cancer: A randomized phase II trial (PRIME-RT). (In-Person Only | Level 1, West Hall; Online Only) -  Dec 4, 2021 - Abstract #ASCOGI2022ASCO_GI_622;    
    P2
    Eligible patients are randomised to Arm A: short course radiotherapy (25 Gray in 5 fractions) with concomitant durvalumab, followed by durvalumab and FOLFOX chemotherapy, or Arm B: long course chemoradiotherapy (50 Gray to primary tumour, 45 Gray to elective nodes, in 25 fractions with capecitabine) with concomitant durvalumab followed by FOLFOX and durvalumab...After opening in January 2021, three patients have been treated within the safety run-in; 2 in Arm A and 1 in Arm B. Early recruitment to PRIME-RT has shown that adding immunotherapy in the neoadjuvant setting for LARC is feasible. The expectation is that the trial will provide efficacy and safety information which allows the optimal treatment approach to be tested within a larger phase clinical trial.
  • ||||||||||  CYAD-101 / Celyad Oncology, Keytruda (pembrolizumab) / Merck (MSD)
    KEYNOTE-B79 phase 1b trial to evaluate the allogeneic CAR T-cells CYAD-101 and pembrolizumab in refractory metastatic colorectal cancer patients. (In-Person Only | Level 1, West Hall; Poster Board - N10) -  Dec 4, 2021 - Abstract #ASCOGI2022ASCO_GI_618;    
    P1, P1b
    The co-primary endpoints of the trial are the occurrence of dose-limiting toxicities (DLTs) at any time from the first FOLFOX preconditioning treatment up to 3 weeks after the first pembrolizumab treatment and the objective response rate (ORR) at the tumor assessment planned 6 weeks after the first pembrolizumab treatment administration. The KEYNOTE-B79 study will be initiated in Q4-2021 in five sites in USA and Europe.
  • ||||||||||  Avastin (bevacizumab) / Roche, Focus V (anlotinib) / Advenchen, Sino Biopharm
    Anlotinib combined with mXELIRI as second-line treatment in advanced colorectal cancer pretreated with bevacizumab plus standard chemotherapy: A single-arm, phase IB/II study. (In-Person Only | Level 1, West Hall; Online Only) -  Dec 4, 2021 - Abstract #ASCOGI2022ASCO_GI_611;    
    P1/2
    Background: For advanced colorectal cancer (CRC), fluoropyrimidine-based chemotherapy (5-FU or capecitabine combined with oxaliplatin) with VEGF inhibitors (bevacizumab) is standard first-line treatment...mXELIRI is a chemotherapy regimen consisting of irinotecan and capecitabine...Secondary endpoints are progression-free survival (PFS), overall survival (OS), disease control rate (DCR), duration of response (DOR) and quality of life (QoL). Based on a one-sided one sample log-rank test with 2.5% Type I error, 80% power to detect an improvement in ORR from 5.4% to 15%, there will be 94 patients consider 20% of patients fall off.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
    Encorafenib, cetuximab, and cytotoxic chemotherapy combinations in BRAFV600E CRC murine models. (In-Person & On Demand | Level 1, West Hall; Poster Board - K9) -  Dec 4, 2021 - Abstract #ASCOGI2022ASCO_GI_535;    
    Taken together, results from our study suggest that the addition of chemotherapy to BRAF+EGFR targeted therapy can further increase the magnitude of response in BRAFV600E mCRC and is a promising combination now being explored clinically. Additionally, this research will substantially contribute to our understanding of the genetic and molecular bases of resistance to target therapies and chemo-based approach in BRAFV600Econtext.
  • ||||||||||  capecitabine / Generic mfg.
    Tumor volume regression of rectal cancer in daily MRI during preoperative chemoradiotherapy with capecitabine. (In-Person & On Demand | Level 1, West Hall; Poster Board - M1) -  Dec 4, 2021 - Abstract #ASCOGI2022ASCO_GI_515;    
    Steady pattern of tumor regression may be explained in part by daily administration of capecitabine. Based on the hypothesis-generating observation, this study may warrant initiation of further investigations such as analysis and comparison with daily tumor volume regression with CCRT using leucovorin and 5-FU.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
    Modified FOLFIRINOX (mFOLFIRINOX) in high risk locally advanced rectal adenocarcinomas. (In-Person & On Demand | Level 1, West Hall; Poster Board - L10) -  Dec 4, 2021 - Abstract #ASCOGI2022ASCO_GI_503;    
    Locally advanced rectal cancers with high-risk characteristics are a niche group of cancers with less-than-optimal outcomes post standard neoadjuvant strategies. mFOLFIRINOX appears to be well tolerated in this cohort of patients and enables conversion to curative local resection and potentially improves survival as well.
  • ||||||||||  Changes in prescribing patterns in stage III colon cancer (CC) since the IDEA collaboration. (In-Person & On Demand | Level 1, West Hall; Poster Board - E4) -  Dec 4, 2021 - Abstract #ASCOGI2022ASCO_GI_487;    
    Our findings suggest that since IDEA, physician practice has significantly changed in favor of CAPOX and shorter courses of Rx. The use of CAPOX has significantly increased overall, presumably due to its efficacy across all risk groups and relatively reduced toxicity.
  • ||||||||||  5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
    Second cancer after adjuvant chemotherapy in patients with colon cancer. (In-Person & On Demand | Level 1, West Hall; Poster Board - L6) -  Dec 4, 2021 - Abstract #ASCOGI2022ASCO_GI_482;    
    Second cancer development was not increased after adjuvant chemotherapy for UICC-stage III/IV colon cancer, which is a novel aspect in the ongoing discussions on reduction of adjuvant treatment to 3 months or treatment of lymph node negative patients. Primary tumor (N) Second tumor (N) Second tumor (%) Cumulative rate 60 months (%) Log-Rank p Chemotherapy Yes 1520 145 9.5% 8.8% No 1336 78 5.8% 9.0% 0.685 Total 2856 223 7.8% 8.9%
  • ||||||||||  Avastin (bevacizumab) / Roche
    Integrated approach to collecting patient reported toxicities in a colorectal cancer trial. (In-Person & On Demand | Level 1, West Hall; Poster Board - C4) -  Dec 4, 2021 - Abstract #ASCOGI2022ASCO_GI_448;    
    Nevertheless, discordance continues to exist between patient-reported and clinician-reported toxicity ratings, consistent with prior research. Further research could formally compare concordance when using an integrated vs a non-integrated toxicity rating workflow and could ascertain the reasons for continued discordance within an integrated workflow.
  • ||||||||||  Cyramza (ramucirumab) / Eli Lilly
    Randomized phase II selection study of ramucirumab and paclitaxel versus FOLFIRI in refractory small bowel adenocarcinoma: SWOG S1922. (In-Person Only | Level 1, West Hall; Poster Board - R5) -  Dec 4, 2021 - Abstract #ASCOGI2022ASCO_GI_384;    
    P2
    This is a randomized phase II selection design clinical trial of FOLFIRI (5-fluorouracil, leucovorin and irinotecan) every two weeks or ramucirumab D1,15 and paclitaxel D1,8,15 every 4 weeks with the primary endpoint of progression-free survival (PFS)...Key eligibility include having mismatch repair proficient/microsatellite stable small bowel adenocarcinoma (ampullary location excluded); metastatic or locally advanced unresectable disease; prior fluoropyrimidine and/or oxaliplatin therapy; no prior treatment with irinotecan, ramucirumab, or taxanes; no recent bleeding, blood clots, or bowel perforation/fistula; and Zubrod performance status of 0/1...This trial is open and, as of September 1, 2021, 17 of 94 planned patients have been enrolled. NCT04205968.
  • ||||||||||  Abraxane (albumin-bound paclitaxel) / BMS, Otsuka
    A phase I study of first-line L-glutamine (Gln) with gemcitabine (gem) and nab-paclitaxel (nab-p) in advanced pancreatic cancer (GlutaPanc). (In-Person Only | Level 1, West Hall; Online Only) -  Dec 4, 2021 - Abstract #ASCOGI2022ASCO_GI_379;    
    P1
    Background: Cytotoxic chemotherapy remains the preferred first-line treatment for advanced or unresectable pancreatic cancer with combination regimens including 5-fluoruracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX), or gem and nab-p...Secondary objectives are to describe any preliminary evidence of antitumor activity by assessment of objective response rate, progression-free survival, and overall survival. Since October 2020, 3 patients have been screened and 3 enrolled.
  • ||||||||||  Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka, Abraxane (albumin-bound paclitaxel) / BMS, Otsuka
    Randomized multicenter phase II/III study of gemcitabine plus nab-paclitaxel or modified FOLFIRINOX or S-IROX in patients with metastatic or recurrent pancreatic cancer (JCOG1611, GENERATE). (In-Person Only | Level 1, West Hall; Online Only) -  Dec 4, 2021 - Abstract #ASCOGI2022ASCO_GI_370;    
    GnP is consisted of nab-paclitaxel (125 mg/m2) and gemcitabine (1000 mg/m2) on days 1, 8, and 15, every 4 weeks, modified FFX is consisted of oxaliplatin (85 mg/m2), irinotecan (150 mg/m2), l-leucovorin (200 mg/m2), and fluorouracil (2400 mg/m2, 46-hour continuous infusion), every 2 weeks, and S-IROX is consisted of oxaliplatin (85 mg/m2), irinotecan (150 mg/m2) and S-1 (80 mg/m2, days 1-7), every 2 weeks...The study started patient accrual in April 2019 and 349 patients have been enrolled as of September 2021. Clinical trial registry: jRCTs031190009.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
    A multi-institutional, single-arm, phase II trial of neoadjuvant modified-FOLFIRINOX for resectable pancreatic ductal adenocarcinoma. (In-Person Only | Level 1, West Hall; Online Only) -  Dec 4, 2021 - Abstract #ASCOGI2022ASCO_GI_367;    
    To increase the survival, various peri-operative treatments have been tested, and adjuvant FOLFIRINOX or gemcitabine plus capecitabine is now standard of care after surgical resection for localized PDAC...Patients receive oxaliplatin 85 mg/m2 D1 + leucovorin 400mg/m2 D1 + irinotecan 150 mg/m2 D1 + 5-FU 2,000 mg/m2 46h continuous infusion, every other week for 6 cycles (12 weeks)...The study will enroll up to 27 patients and is currently recruiting at four sites in South Korea. As of September 2021, 20 patients have been enrolled.
  • ||||||||||  zolbetuximab (IMAB362) / Astellas
    Zolbetuximab + CAPOX versus CAPOX in first-line treatment of claudin18.2+/HER2– advanced/metastatic gastric or gastroesophageal junction adenocarcinoma: GLOW phase 3 study. (In-Person Only | Level 1, West Hall; Poster Board - M3) -  Dec 4, 2021 - Abstract #ASCOGI2022ASCO_GI_176;    
    P2, P3
    2021) results showed prolonged survival with zolbetuximab + EOX (epirubicin, oxaliplatin, capecitabine) vs EOX in CLDN18.2+ advanced G/GEJ...2021) results showed promising antitumor activity with combination zolbetuximab + mFOLFOX6 (5-fluorouracil, folinic acid, oxaliplatin) in CLDN18.2+ advanced G/GEJ...Secondary endpoints: overall survival; objective response rate; duration of response; safety/tolerability, pharmacokinetics, and immunogenicity of zolbetuximab. As of September 22, 2021, 135 sites were open for screening and enrollment.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    A phase II study of perioperative mFOLFOX chemotherapy plus pembrolizumab combination in patients with potentially resectable adenocarcinoma of the esophageal, gastroesophageal junction (GEJ), and stomach. (Live Stream | Level 1, West Hall; Poster Board - G7) -  Dec 4, 2021 - Abstract #ASCOGI2022ASCO_GI_115;    
    P2
    Patients with newly diagnosed locally advanced (T1N1-3M0 or T2-3NanyM0), potentially resectable adenocarcinoma of distal esophagus, GEJ and stomach by PET, EUS, CT C/A/P and staging laparoscopy were treated with pre-operative mFOLFOX6 (oxaliplatin 85mg/m2, Leucovorin 400mg/m2, 5-FU bolus 400mg/m2, and 5-FU 2400mg/m2 infusion every 2 weeks) for 4 cycles and pembrolizumab (200 mg IV q3week) for 3 cycles... The combination of FOLFOX and pembrolizumab as peri-operative (pre- and post-operative) therapy in patients with locally advanced adenocarcinoma of distal esophagus, GEJ and stomach is safe and preliminary benefit data are very encouraging with ypRR of 92% and ypCR of 19% and supporting the combination of chemotherapy and Immune checkpoint inhibitor at perioperative setting.